OBJECTIVE: To systematically evaluate the efficacy and safety of Shexiang Baoxin Pills in the treatment of coronary heart disease and angina pectoris.METHODS: CNKI

VIP database

Wanfang database and PubMed were retrieved to collect the randomized controlled trial of Shexiang Baoxin Pills in the treatment of coronary heart disease and angina pectoris（ the study group was treated with Shexiang Baoxin Pills alone or combined with conventional treatment

while the control group received Isosorbide mononitrate tablets alone or combined with conventional treatments）. The retrieval time was from the establishment of the database to Jan.2020

and the retrieval terms were "Shexiang Baoxin Pills"

"Isosorbide mononitrate tablets"and"coronary heart disease and angina pectoris".RevMan 5. 3 software was used for Meta-analysis.RESULTS: Totally 16 literature were included.Meta-analysis results showed that the clinical treatment effective rate（ OR = 3. 47

95%CI = 2. 45-4. 91

P<0. 000 01） and ECG effective rate（ OR = 2. 40

95%CI = 1. 88-3. 07

P<0. 000 01） in the study group were significantly better than those in the control group

and the incidence of adverse drug reactions was significantly lower than that of the control group（ OR = 0. 24

95%CI = 0. 15-0. 39

P<0. 000 01）

and the differences were statistically significant.CONCLUSIONS: Compared with the treatment of Isosorbide mononitrate tablets

the efficacy of Shexiang Baoxin Pills in the treatment of coronary heart disease and angina pectoris is significant and the incidence of adverse drug reactions is lower. However

due to the small sample size and low quality of the included literature

the conclusion needs to be further verified.